Argos Therapeutics

Argos Therapeutics, Inc. is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company is pioneering the development of individualized immunotherapy, using its combined mRNA and dendritic cell technology to deliver specifically targeted treatments, one patient at a time. Using material from both disease and blood samples collected from each patient, its Arcelis-based immunotherapies arm the patient’s dendritic cells to trigger a targeted patient-specific immune response.

Company Growth (employees)
Type
Public
HQ
Durham, US
Founded
1997
Size (employees)
122 (est)-10%
Argos Therapeutics was founded in 1997 and is headquartered in Durham, US

Argos Therapeutics Office Locations

Argos Therapeutics has an office in Durham
Durham, US (HQ)
4233 Technology Dr

Argos Therapeutics Financials and Metrics

Argos Therapeutics Financials

Argos Therapeutics's revenue was reported to be $105.3 k in Q1, 2017
USD

Revenue (Q1, 2017)

105.3 k

Net income (Q1, 2017)

(24.1 m)

EBIT (Q1, 2017)

(44 m)

Market capitalization (19-Oct-2017)

6.8 m
Argos Therapeutics's current market capitalization is $6.8 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

2 m518.3 k945.5 k

Revenue growth, %

(74%)82%

R&D expense

45.5 m62.1 m38.3 m

General and administrative expense

8.6 m11 m14.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

473.2 k398.6 k178.8 k107.4 k158.3 k146.4 k488.6 k146.8 k105.3 k

R&D expense

10.6 m13 m14.8 m16.1 m17.2 m9.5 m9.2 m9.3 m7.9 m

General and administrative expense

1.9 m2.3 m2.4 m2.9 m2.7 m3 m3.4 m3 m4 m

Operating expense total

12.4 m15.3 m17.1 m19 m19.9 m12.5 m12.6 m12.4 m11.9 m
USDFY, 2014FY, 2015FY, 2016

Cash

37.2 m6.2 m53 m

Accounts Receivable

129 k73.8 k136.1 k

Current Assets

57.5 m8.8 m55.5 m

PP&E

5.5 m22.3 m41 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

44.3 m50.3 m29 m23 m20 m13.8 m34.8 m69.3 m

Accounts Receivable

265.5 k163.2 k163.7 k57 k130.8 k91.4 k461.1 k119.3 k137.2 k

Current Assets

72.9 m70.9 m40.4 m33 m24.9 m15.5 m37.3 m71.3 m25.5 m

PP&E

1.8 m4.5 m11.2 m15.5 m19 m27.3 m29.1 m37.5 m4.3 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(53.3 m)(74.8 m)(53 m)

Depreciation and Amortization

566.1 k680.4 k952.3 k

Accounts Receivable

(252 k)(629 k)(906 k)

Accounts Payable

543.4 k(137 k)1.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12 m)(15.1 m)(17.5 m)(19.6 m)(20.1 m)(12.8 m)(12.6 m)(12.2 m)(24.1 m)

Accounts Receivable

265.5 k163.2 k163.7 k57 k130.8 k91.4 k461.1 k119.3 k137.2 k

Accounts Payable

2.2 m3.1 m3.6 m4.7 m3.1 m6.2 m5.1 m3.6 m3.4 m
USDY, 2017

Revenue/Employee

816
Show all financial metrics

Argos Therapeutics Market Value History

Traffic Overview of Argos Therapeutics

Argos Therapeutics Online and Social Media Presence

Argos Therapeutics Company Life and Culture

You may also be interested in